Cost Effectiveness of a Pharmacy-Only Refill Program in a Large Urban
                    HIV/AIDS Clinic in Uganda by Babigumira, Joseph B. et al.
Cost Effectiveness of a Pharmacy-Only Refill Program in a
Large Urban HIV/AIDS Clinic in Uganda
Joseph B. Babigumira
1*, Barbara Castelnuovo
2, Andy Stergachis
1,3, Agnes Kiragga
2, Petra Shaefer
2,
Mohammed Lamorde
2, Andrew Kambugu
2, Alice Muwanga
2, Louis P. Garrison
1
1Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, Washington, United States of America, 2Infectious
Diseases Institute, Makerere University, Kampala, Uganda, 3Departments of Epidemiology and Global Health, School of Public Health, University of Washington, Seattle,
Washington, United States of America
Abstract
Background: HIV/AIDS clinics in Uganda and other low-income countries face increasing numbers of patients and
workforce shortages. We performed a cost-effectiveness analysis comparing a Pharmacy-only Refill Program (PRP), a form of
task-shifting, to the Standard of Care (SOC) at a large HIV/AIDS clinic in Uganda, the Infectious Diseases Institute (IDI). The
PRP was started to reduce workforce shortages and optimize patient care by substituting pharmacy visits for SOC involving
monthly physician visits for accessing antiretroviral medicines.
Methodology/Principal Findings: We used a retrospective cohort analysis to compare the effectiveness of the PRP
compared to SOC. Effectiveness was defined as Favorable Immune Response (FIR), measured as having a CD4 lymphocyte
count of over 500 cells/ml at follow-up. We used multivariate logistic regression to assess the difference in FIR between
patients in the PRP and SOC. We incorporated estimates of effectiveness into an incremental cost-effectiveness analysis
performed from a limited societal perspective. We estimated costs from previous studies at IDI and conducted univariate
and probabilistic sensitivity analyses. We identified 829 patients, 578 in the PRP and 251 in SOC. After 12.8 months (PRP) and
15.1 months (SOC) of follow-up, 18.9% of patients had a FIR, 18.6% in the PRP and 19.6% in SOC. There was a non-significant
9% decrease in the odds of having a FIR for PRP compared to SOC after adjusting for other variables (OR 0.93, 95% CI 0.55–
1.58). The PRP was less costly than the SOC (US$ 520 vs. 655 annually, respectively). The incremental cost-effectiveness ratio
comparing PRP to SOC was US$ 13,500 per FIR. PRP remained cost-effective at univariate and probabilistic sensitivity
analysis.
Conclusion/Significance: The PRP is more cost-effective than the standard of care. Similar task-shifting programs might
help large HIV/AIDS clinics in Uganda and other low-income countries to cope with increasing numbers of patients seeking
care.
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Introduction
The HIV/AIDS epidemic in Africa remains a global public
health concern. New infections peaked in 1996 but the number of
persons living with the disease, now 22.4 million, continues to rise,
a result of a high rate of new infections and the life-saving and life-
extending impact of antiretroviral therapy (ART) [1]. With the
prevailing health workforce crisis [2,3], HIV/AIDS clinics must
find innovative ways to organize the way they provide care to
numerous patients with a sub-optimal health workforce. The
Infectious Diseases Institute (IDI), Makerere University, a regional
center of HIV treatment, prevention, training, and research
excellence in Kampala, Uganda, was faced with such a situation in
2006. Its out-patient clinic, which had 2,800 patients on ART in
2005, had grown to 10,000 total patients, half of whom were on
ART and the number of patients was increasing without a
substantial increase in clinical staff, particularly physicians. To
alleviate the growing demand for physician visits and enable as
many patients as possible to be initiated and maintained on
therapy, IDI started a Pharmacy-only Refill Program (PRP).
The PRP was designed to substitute the prevailing Standard of
Care (SOC) involving monthly physician visits with pharmacy-
only monthly visits. Physicians selected patients for the PRP if they
met the following criteria: 1) CD4 lymphocyte count greater than
200 cells/mL, 2) at least 12 months of ART, 3) self-reported
adherence greater than 95%, 4) adherence to scheduled clinic
visits for the preceding 6 months, 5) disclosed HIV status to
spouse, 6) not pregnant, and 7) no substantial clinical event in the
preceding 6 months. PRP-eligible patients picked up their
antiretroviral medicines (ARVs) at the IDI pharmacy during
monthly PRP visits without visiting a physician. However, PRP
patients were asked screening questions by a pharmacy-based
nurse during every PRP visit. It was arranged that PRP patients
see a physician once every six months. Patients enrolled into the
PRP and subsequently judged to have major clinical or social
problems, or who developed problematic adherence to ART, were
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entirely.
The PRP is a form of task-shifting, the delegation of aspects of
healthcare from more to less specialized health workers which has
been proposed as a potential solution to the health workforce crisis
in low-income countries [4,5]. A systematic review of task-shifting
in HIV/AIDS care concluded that it is an effective strategy for
addressing shortages of health workers in Africa and that it offers
high quality, cost-effective care to more patients than a physician-
centered model [6]. Further evidence to support task-shifting has
come from randomized trials which have found that nurse
monitoring is non-inferior to doctor monitoring for the manage-
ment of HIV patients in South Africa [7] and that task-shifting
with persons living with AIDS, supported by personal digital
assistants, results in similar health outcomes as the usual standard
of care [8]. This is in addition to evidence from observational
studies that suggests that task-shifting leads to improvements in
access and good program outcomes for adults [9,10] and children
[11] and that that nurses can effectively and safely prescribe ART
when given adequate training, mentoring, and support [12].
Yet despite the growing evidence of the potential role of task-
shifting in improving HIV/AIDS treatment, policy action has
been apathetic and some have argued that this is unethical [13].
Concerns about task-shifting have been raised by studies that show
that the quality of care may suffer when non-physician clinicians
perform physician duties [14] and a variety of other challenges
remain, including addressing professional and institutional resis-
tance, sustaining motivation and performance, and preventing
deaths of health workers from HIV/AIDS [5].
Cost-effectiveness analysis considers both costs and health
outcomes in evaluating the efficiency of healthcare interventions
and allows policy makers to prioritize among competing uses of
scarce healthcare resources. Cost-effectiveness studies might
contribute to the policy dialogue surrounding HIV/AIDS care
and improve the quality of policy decisions. However, we found
only one study that assessed the costs of task-shifting [15] and none
that assessed its potential cost-effectiveness. Therefore, we
performed a study to estimate the cost effectiveness of the PRP
– a form of task-shifting – as compared to SOC.
Methods
Study design
We performed a retrospective cohort analysis and an incre-
mental cost-effectiveness analysis.
Retrospective cohort study
Using data from the IDI clinic database we retrospectively
identified a cohort of patients treated at IDI in 2005, 2006, and
2007. We defined the exposed (to the PRP) group as patients who
were enrolled in the PRP program in the first 6 months of its initiation
starting in June 2006 and the unexposed (SOC) group as patients that
1) had reached a CD4 lymphocyte count of 200 cells/mla f t e r1y e a r
on ART and 2) after reaching a CD4 lymphocyte count of 200 cells/
ml were followed for at least one year before the start of the PRP
program. The SOC patients were selected from the pre-PRP cohort
so as to obtain a group of patients with similar characteristics. We
started following PRP patients from initiation into the program and
SOC patients from the first visit after achieving a CD4 lymphocyte
count of 200 cells/ml. We excluded patients who had been on ART
for less than one year and patients who were lost to follow-up during
the follow-up period. The main outcome of our evaluation was a
binary variable—whether or not patients had a favorable immune
response (FIR), measured as follow-up CD4 lymphocyte count over
500 cells/ml at follow-up. This cut-off point is the lower limit of
normal for Ugandan populations [16].
Other outcomes included median increase in CD4 lymphocyte
count at follow-up and proportion of patients in different CD4
lymphocyte count ranges. We assessed outcomes as recorded in
the medical records at the clinic visit at which a CD4 lymphocyte
count was available and that was closest in date to 1 year after
initiation of ART. We recorded all available covariates from the
clinic records, i.e., age, gender, duration of ART, initial ART
regimen, current ART regimen, presence/absence of opportunis-
tic infection or neoplasm at baseline and follow-up, self-reported
adherence (visual analog scale), CD4 lymphocyte count at start of
ART, and CD4 lymphocyte count at baseline.
Statistical analysis
We used 2-tailed tests and an a-level of 0.05 for all our analyses.
We present descriptive statistics as differences between patients in
the PRP and SOC groups using the student t-test for means and
chi-square test for proportions. Logistic regression was used to
estimate the odds ratios (ORs) of having a FIR. The ORs are from
unadjusted models (crude ORs) and from models adjusted for
possible confounders regardless of statistical significance at
univariate analysis. We performed statistical analyses using
STATA 9.1, College Station TX.
Determination of costs
We separated the cost of implementing the PRP and SOC into
the following categories: ART, other drugs, radiology, laboratory
tests, health personnel, overhead and capital, patient transport,
and lost patient time. We obtained costs of ART, other drugs,
laboratory tests and radiology from a previous study at IDI in
which investigators conducted a retrospective review of medical
records to estimate resource utilization [17]. We obtained costs of
health personnel and lost patient time from previous studies at IDI
which included a time-and-motion survey to estimate health
worker and patient time use [18] and a cost-minimization study in
which data on health worker and patient wages were combined
with data from the time-and-motion survey [15]. We obtained
overhead and annualized capital costs from the World Health
Organization Choosing Interventions that are Cost-Effective
(WHOCHOICE) database for Uganda [19]. The annual costs
were as follows: ART, $243; other drugs, $35; radiology, $2;
laboratory tests, $34; health personnel (PRP), $10; health
personnel (SOC), $31; overhead and capital costs, $141; patient
transport, $20; lost patient time (PRP), $4; and lost patient time
(SOC), $16. All costs are in 2009 US dollars.
Cost-effectiveness analysis
We performed an incremental cost-effectiveness analysis from
the ‘‘limited’’ societal and Ministry of Health (MoH) perspectives.
The limited societal perspective [20] refers to analyses which do
not meet the full criteria of the reference case as defined by the
Panel on Cost-Effectiveness [21]. In our study, this perspective
included all the different cost categories described above (direct
medical and direct non-medical costs) but did not include
productivity losses due to morbidity and mortality (indirect costs).
The MoH perspective was included because the MoH is the
relevant payer in Uganda since the country has a national health
service that, in theory, should provide health care to all citizens.
The MoH perspective only included direct medical costs and
excluded direct non-medical costs (patient transport and lost
patient time). The outcome of the analysis was cost per FIR over
the 13-month follow-up period. This intermediate outcome was
used in the analysis because patients in our study population have
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more appropriate outcome to be measured.
Uncertainty analysis
To ascertain the robustness of our results, we performed one-
way and probabilistic sensitivity analyses. Cost estimates were
halved and doubled and probabilities were reduced or increased
by 20%. We created probability distributions for all of the
parameters (probability of FIR and costs) in the model. For
different parameters we used the baseline value for the mean, and
estimated the standard error based on the approximation that the
range used for the one-way sensitivity analysis represented a 95%
confidence interval. We used a beta distribution for proportions
and a gamma distribution for costs. We used Monte Carlo
simulation to create 10,000 samples for which expected values
were calculated. We examined a scatter plot of incremental cost
and effectiveness pairs on the cost-effectiveness plane to examine
the relative proportion that lay in the different quadrants. The
scatter plot was also used to examine the uncertainty surrounding
whether or not the PRP would be cost-effective and at what value
it would be cost-effective. To summarize this uncertainty and
better estimate potential decision uncertainty, we also calculated
the proportion of iterations for which the PRP was cost-effective
relative to SOC varying limits of cost-effectiveness (willingness to
pay), and generated a cost-effectiveness acceptability curve. Cost-
effectiveness analysis was performed using TreeAge Pro, TreeAge
Software Inc, Williamstown, MA.
The study was approved by the Makerere University Faculty of
Medicine Research and Ethics Committee (number 2009-120) and
the Uganda National Council for Science and Technology
(number HS 683). The Ethics Committee has approved the
performance of evaluations using secondary clinic data without
patient consent and has set standards for maintaining confiden-
tiality including analysis after stripping data of unique personal
identifiers, holding charts in secure locked locations, and
protecting databases with passwords accessible to study staff
members only.
Results
Baseline characteristics
We enrolled 829 patients in the analysis, 578 in the PRP group
and251inSOC group.Table 1 shows thedescriptivedemographic,
clinical and laboratory characteristics of the cohorts by exposure
status. PRP patients were followed for a significantly shorter period
of time (12.8 vs. 15.1 months; p-value,0.001), were older (38.8 vs.
35.7 years; p-value,0.001), had been on ART longer (41.8 vs. 30.9
months; p-value,0.001) and had lower baseline CD4 lymphocyte
counts (218 vs. 292 cells/ml; p-value,0.001). PRP and SOC
patients were also significantly different by initial and current ART
regimen, presence or absence of opportunistic infections at baseline
and follow-up, and proportion with sub-optimal adherence. The
exposure groups were not different by gender and CD4 lymphocyte
count at start of ART.
Table 1. Demographic, clinical and laboratory characteristics of the study population by method of follow-up
a.
Category Sub-category SOC (%) PRP (%) Total (%) p-value
Time (baseline to follow-up) 12.8 (1.6) 15.1 (1.3) 13.5 (1.9) ,0.001
Age, years 38.8 (7.5) 35.9 (7.5) 36.8 (7.6) ,0.001
Gender Male 100 (39.8) 253 (43.8) 353 (42.6) 0.293
Female 151 (60.2) 325 (56.2) 476 (57.4)
ART duration (months) 41.8 (16.2) 30.9 (13.0) 34.2 (14.9) ,0.001
Initial ART regimen d4T-3TC-NVP 160 (63.8) 362 (62.6) 522 (63.0) ,0.001
ZDV-3TC-EFV 51 (20.3) 194 (33.6) 245 (11.2)
Other* 40 (15.9) 22 (3.8) 62 (7.5)
Current ART regimen ZDV-3TC-NVP 52 (20.7) 167 (29.9) 219 (26.4) ,0.001
ZDV-3TC-EFV 37 (14.7) 154 (26.6) 191 (23.0)
ZDV-TDF-FTC-LPV/r 33 (13.5) 165 (28.6) 198 (23.9)
Other** 129 (51.4) 92 (15.9) 221 (26.6)
OI at baseline None 216 (86.1) 544 (94.1) 760 (91.7) ,0.001
1 or more 35 (13.9) 34 (5.9) 69 (8.3)
OI at follow-up None 220 (93.4) 540 (87.6) 760 (91.7) 0.006
1 or more 31 (6.6) 38 (12.4) 69 (8.3)
Adherence
Y ,95% 26 (11.1) 9 (1.6) 35 (4.3) ,0.001
.95% 208 (88.9) 564 (98.4) 772 (95.7)
CD4 count (start of ART) 121 (131) 124 (103) 123 (112) 0.758
CD4 count (start of study) 218 (160) 292 (145) 268 (154) ,0.001
aAll data are n (%) or mean (SD).
*Includes d4T-3TC-EFV, ZDV-3TC-NVP, NVP-TDF-3TC, ZDV-ddI-LPV/r, ZDV-3TC-LPV/r, ddI-d4T-LPV/r, ZDV-EFV-LPV/r, 3
rd line drugs and unknown drugs.
**Includes D4T-3TC-NVP, D4T-3TC-EFV, TDF-FTC-EFV, NVP-TDF-3TC, TDF-FTC-NVP, ZDV-DDI-LPV/r, ZDV-3TC-LPV/r, DDI-D4T-LPV/r, TDF-FTC-LPV/r, ZDV-TDF-LPV/r, ZDV-
3TC-DDI-LPV/r , TDF-EFV-LPV/r, 3TC-NVP-LPV/r and other 3
rd line drugs.
YN=807.
SOC: standard of care; PRP: Pharmacy Refill Program; ART: antiretroviral treatment; d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; ZDV: zidovudine; EFV: efavirenz;
TDF: tenofovir; FTC: emtricitabine; LPV/r: lopinavir/ritonavir; OI: opportunistic infection.
doi:10.1371/journal.pone.0018193.t001
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At baseline, 8.1% of cohort members had a CD4 lymphocyte
count above 500 cells/ml, 5.7% in the PRP group and 9.5% in the
SOC group. At follow-up, 18.9% of cohort members had a FIR,
19.6% in the PRP group and 18.6% in the SOC group. Median
CD4 lymphocyte count increase between baseline and follow-up
was 53 cells/ml in the PRP group and 128 cells/ml in the SOC
group. At follow-up the proportion of patients with CD4 less than
200 cell/ml, 200–350 cells/ml, 350–500 cells/ml and above 500
cells/ml were 30.0%, 15.1%, 39.4%, 25.5%, 19.9% respectively in
the PRP group and 14.6%, 40.2%, 26.7%, 18.6% respectively in
the SOC group. Table 2 shows the results of the univariate and
multivariate logistic regression analysis comparing PRP and SOC.
There was a non-significant 9% decrease in the odds of having a
FIR for PRP compared to SOC after adjusting for other variables.
Cost effectiveness analysis
Table 3 shows the results of the cost-effectiveness analysis. The
mean costs were lower in the PRP group than in the SOC group
($520 vs. $655 from the societal perspective and $496 vs. $610
Table 2. Univaraite and multivariate logistic regression analysis of variables associated with follow-up CD4 cell count over 500
cells/ul (n=807).
Variable Sub-category Unadjusted OR (95% CI) p-value Adjusted OR (95% CI) p-value
Exposure status SOC 1 [Reference] 1 [Reference]
PRP 0.93 (0.72–1.60) 0.737 0.93 (0.55–1.58) 0.797
Duration of follow-up ,1 year 1 [Reference] 1 [Reference]
.1 years 1.53 (1.01–2.33) 0.045 1.98 (1.19–3.25) 0.007
Duration of ART ,2 years 1 [Reference] 1 [Reference]
2–3 years 1.12 (0.66–1.90) 0.682 0.84 (0.47–1.52) 0.570
.3 years 0.56 (0.33–0.96) 0.035 0.34 (0.18–0.65) ,0.001
Age 1.02 (0.99–1.05) 0.072 1.02 (0.99–1.04) 0.286
Gender Male 1 [Reference] 1 [Reference]
Female 0.44 (0.29–0.66) ,0.001 0.47 (0.30–0.73) ,0.001
Initial ART regimen d4T-3TC-NVP 1 [Reference] 1 [Reference]
ZDV-3TC-EFV 1.61 (1.03–2.52) 0.035 2.45 (0.81–7.35) 0.109
Other* 1.01 (0.49–2.00) 0.988 1.09 (0.47–2.54) 0.833
Current ART regimen ZDV-3TC-NVP 1 [Reference] 1 [Reference]
ZDV-3TC-EFV 1.48 (0.86–2.52) 0.152 0.62 (0.18–2.11) 0.442
ZDV-TDF-FTC-LPV/r 0.99 (0.61–1.64) 0.952 1.03 (0.61–1.85) 0.903
Other** 1.51 (0.89–2.53) 0.120 1.68 (0.91–3.11) 0.098
OI at baseline None 1 [Reference] 1 [Reference]
1 or more 1.62 (0.76–3.49) 0.214 1.68 (0.75–3.79) 0.210
OI at follow-up None 1 [Reference] 1 [Reference]
1 or more 0.85 (0.44–1.61) 0.611 0.83 (0.40–1.69) 0.602
Adherence
Y Sub-optimal 1 [Reference]
Optimal 1.33 (0.59–3.01) 0.490 1.37 (0.55–3.39) 0.501
CD4 count at start of ART ,200 1 [Reference] 1 [Reference]
200–300 0.44 (0.28–0.69) 0.001 0.44 (0.27–0.72) ,0.001
.300 0.36 (0.19–0.69) 0.002 0.39 (0.19–0.78) 0.008
OR: odd ratio; SOC: standard of care; PRP: Pharmacy Refill Program; ART: antiretroviral treatment; d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; ZDV: zidovudine; EFV:
efavirenz; TDF: tenofovir; FTC: emtricitabine; LPV/r: lopinavir/ritonavir; OI: opportunistic infection.
doi:10.1371/journal.pone.0018193.t002
Table 3. Mean and incremental costs, probability of CD4 cell count over 500 cell/ul at 1 year and cost-effectiveness comparing PRP
and standard care in patients on antiretroviral treatment at the IDI clinic, Kampala, Uganda.
Societal
Cost*(US$)I n c .
Healthcare
Cost* Inc.
Probability
of FIR Inc.
Limited Societal
ICER (US$/FIR) MoH ICER (US$/FIR)
SOC 655 – 610 – 0.196 – –
PRP 520 2135 496 2114 0.186 20.010 13,500 11,400
Inc. – Incremental; ICER: Incremental Cost-Effectiveness Ration; FIR – Favorable Immune Response; PRP: Pharmacy-Only Refill Program; SOC – Standard of Care.
*All costs are per person per year.
doi:10.1371/journal.pone.0018193.t003
Efficiency of Pharmacy Refill
PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e18193from the MoH perspective). The probability of FIR was also lower
in the PRP group compared to the SOC group (0.186 vs. 0.196).
The incremental cost-effectiveness ratio for PRP compared to
SOC was $13,500 per FIR from the societal perspective and
$11,400 from the MoH perspective. These ICERs lie in the
‘‘southwest’’ quadrant of the cost-effectiveness plane and may be
interpreted as follows: the PRP leads to one less FIR than the SOC
at an incremental savings of $13,500 from the limited societal
perspective or $11,400 from the MoH perspective.
Univariate sensitivity analyses showed that the incremental cost
(Figure 1) was most sensitive to the cost of antiretroviral
medication and that the incremental effectiveness was most
sensitive to probability of favorable immune response.
Figure 2 is a scatter plot that illustrates the uncertainty in the
expected incremental cost and FIR. All Monte Carlo replicates
comparing PRP to SOC lie below zero on the cost axis, indicating
a high degree of certainty that PRP is less costly than SOC. Data
points that lie in the ‘‘southwest’’ quadrant of the cost-effectiveness
plane represent a loss in the probability of FIR at a decreased cost
for PRP compared to SOC. Points that lie in the ‘‘southeast’’
quadrant represent a gain in the probability of FIR at a decreased
cost of PRP compared to SOC. The spread of points in the vertical
axis indicates some uncertainty in the magnitude of cost savings
attributed to PRP.
With regard to effectiveness, the location and spread of the
points indicate a high degree of uncertainty in the existence and
extent of the reduction in benefit in FIR comparing PRP to SOC
at follow-up. This is consistent with the finding of a non-significant
decrease in odds of FIR for PRP compared to SOC in the
multivariate logistic regression analysis.
Figure 3 shows the results of the probabilistic sensitivity analysis
presented as a cost-effectiveness acceptability curve. It indicates
Figure 1. Tornado diagram of univariate sensitivity analysis showing the impact on incremental costs comparing Pharmacy-only
Refill Program (PRP) versus Standard of Care (SOC).
doi:10.1371/journal.pone.0018193.g001
Figure 2. Scatter plot of estimated joint density of incremental costs and incremental effects of Pharmacy-only Refill Program (PRP)
versus Standard of Care (SOC) by Monte Carlo simulation.
doi:10.1371/journal.pone.0018193.g002
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larger proportion of iterations compared to SOC. The situation
changes in favor of SOC at a willingness to pay of approximately
$13,000 per FIR.
Discussion
Using a retrospective cohort study and incremental cost-
effectiveness analysis, we performed an evaluation of the
Pharmacy-only Refill Program (PRP) in a large urban HIV clinic
in Kampala, Uganda. Our study suggests that, judging from FIR
measured as the proportion of patients who have a CD4
lymphocyte count over 500 cells/ml at follow-up, the PRP was
not significantly different from SOC and was more cost-effective.
The results were robust to univariate and probabilistic sensitivity
analysis. Our findings represent a common situation in low-
income countries—a healthcare policy intervention that results in
a slight loss in effectiveness but leads to cost savings. We found that
the PRP would lead to one less FIR than the SOC at an
incremental savings of $13,500 from the limited societal
perspective and $11,400 from the MoH perspective. This is a
substantial amount of money in a country with a per capita
expenditure on health care of less than US$30 [22]. With such a
severe budget constraint, the rational choice may be to implement
the PRP, particularly given the evidence of a non-significant
reduction in FIR at multivariate analysis.
A key strength of our study was the combination of an impact
evaluation based on a retrospective cohort study with a cost-
effectiveness analysis supported by probabilistic sensitivity analysis.
The impact evaluation showed that there was a small and not
statistically significant increase in odds of FIR at follow-up for the
SOC. Based on effectiveness alone, one might conclude that either
follow-up strategy is equally effective. But after performing the cost-
effectiveness analysis and sensitivity analysis, PRP appears to be the
better strategy because of the lower cost compared to SOC despite
the lack of a statistically significant difference in FIR between the
two strategies. We also quantified decision uncertainty around the
estimate of incremental cost-effectiveness using a cost-effectiveness
acceptability curve. This is particularly important give the results of
the impact evaluation showing no difference between PRP and
SOC.
Our study had weaknesses that we propose as caveats to the
interpretation of our results. We used an intermediate outcome—
CD4 lymphocyte count. While this outcome is a reasonable
measure of clinical progress in HIV/AIDS patients, the optimal
study would follow patients over their lifetime and compare life-
years. In addition to lifetime follow-up, the ideal study would also
assess the patients’ satisfaction and quality of life which were
beyond the scope of our study.
Additionally, despite performing a multivariate analysis, the more
favorable outcomes of our PRP patients may well reflect residual
selection bias. Only patients who fulfilled all of the criteria were
enrolled into the PRP. Some of their unmeasured characteristics
may affect our effectiveness estimate. A more formal assessment of
the relativeeffectiveness of PRP in ART management would require
a randomized controlled trial. A recent randomized controlled trial
in South Africa found that nurses were non-inferior to doctors when
monitoring the treatment of HIV patients on ART [7]. Another
cluster randomized trial in Uganda found that patients receiving
home-based support, monitoring, and drug delivery by lay workers
with 6-monthly routine evaluation achieved favorable and compa-
rable outcomes to patients receiving facility-based care with monthly
visitsfor drug refilland 3-monthly evaluation [23].Wefound no trial
directly comparing doctor follow-up to pharmacy-only follow-up.
Other studies have found that non-physician care, also called
task-shifting, in low-income countries achieves favorable and
comparable outcomes to physician care [7,8,9,10,11,12] and may
achieve cost savings [15]. To our knowledge, this is the first cost-
effectiveness evaluation of a pharmacy refill program in this setting
and the first evaluation of non-physician care to include costs and
outcomes in the same analysis.
In conclusion, our study suggests that a pharmacy-only refill
program may be a viable and efficient service delivery option for
delivery of ART to eligible patients in Uganda and other low-
income countries which are seeking innovative ways to optimize
resource allocation to large patient populations, particularly in the
face of the current crisis of health workers. Practitioners and clinic
managers, as well as policy makers in this setting might consider
similar programs or start discussions to widely implement them.
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